See footnote about the use of pro forma financial information First Quarter 2016 Highlights: Core recurring revenue (excluding OEM and other revenue) increased 6.8% to $20.5 million compared to core pro forma recurring revenue of $19.2 million in first quarter 2015 Gross profit increased slightly

BELGRADE, Mont. , April 27, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the period ended March 31st, 2016 , at the close of

BELGRADE, Mont. , April 26, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the awarding of two grants from the Montana Department of Commerce totaling $155,000 to aid Bacterin

Core recurring revenue to increase 7% to 8% over first quarter 2015 The Company reiterates full-year 2016 revenue guidance of $94 million to $99 million and EBITDA guidance of $4.3 million to $6.3 million BELGRADE, Mont. , April 19, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc.

BELGRADE, Mont. , March 30, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that its wholly owned subsidiary, X-spine Systems, received FDA clearance of the Xspan™ Laminoplasty

BELGRADE, Mont. , March 24, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a leader in the development of regenerative medicine products and medical devices, is expanding its biologics portfolio through a distribution relationship with Vivex Biomedical, Inc.

See footnote about the use of pro forma financial information Fourth Quarter 2015 Highlights: Consolidated total revenue increased 14.1% to a record $22.3 million compared to pro forma fourth quarter 2014 revenue of $19.5 million Consolidated gross profit increased 14.9% to $14.9 million compared

BELGRADE, Mont. , March 08, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the period ended December 31st, 2015 , at the close of

BELGRADE, Mont. , March 03, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced CE clearance for its products Aranax™ and Irix-A™. The Aranax™ Cervical Plating System is distributed

BELGRADE, Mont. , Feb. 16, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), formerly Bacterin International Holdings, Inc. , a leader in the development of class-leading regenerative medicine products and medical devices, today announced that its Chief Executive Officer, Dan